Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Cited by (578)

Items 401–500 of 578

1. Buprenorphine implants in medical treatment of opioid addiction
   Steven E. Chavoustie, Michael Frost, Ole Snyder, Joel S. Owen, Mona Darwish, Ryan S. Dammerman, Victoria Sanjurjo · 2017 · Expert Review of Clinical Pharmacology
2. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail
   Richard Soper, Sireesh Appajosyula, Christina Deximo · 2018 · Advances in Therapy
3. Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
   Shane W Kaski, Patrick J. Marshalek, Jeremy Herschler, Sijin Wen, Wanhong Zheng · 2021 · Journal of Clinical Medicine
4. Predictors of concurrent heroin use among patients on opioid maintenance treatment in France: a multilevel study over 11 years
   Éric Janssen, Mike Vuolo, Stanislas Spilka, Guillaume Airagnes · 2024 · Harm Reduction Journal
5. Are Methadone Counselors Properly Equipped to Meet the Palliative Care Needs of Older Adults in Methadone Maintenance Treatment? Implications for Training
   Nick Doukas · 2014 · Journal of Social Work in End-of-Life & Palliative Care
6. Opioid-dependence treatment in the era of recovery: insights from a UK survey of physicians, patients and out-of-treatment opioid users
   Annette Dale‐Perera, Farrukh Alam, Peter Barker · 2014 · Journal of Substance Use
7. Buprenorphine‐associated gastroparesis during in‐patient heroin detoxification
   Simon L. Jakobovits, Michael Mcdonough, Robert Yuzen Chen · 2007 · Addiction
8. Eficacia clínica de la buprenorfina
   Carlos Roncero, Miguel Casas · 2005 · Trastornos Adictivos
9. Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts
   Thomas F. Kresina, Leonard B. Seeff, Henry L. Francis · 2004 · Hepatology
10. Open-Label Exploration of an Intravenous Nalbuphine and Naloxone Mixture as an Analgesic Agent Following Gynecologic Surgery
    Assaf T. Gordon, Jon D. Levine, Michel Y. Dubois, Robert DʼAngelo, Ann Marie Conlon, Danijela Levacic, Allen Lebovits · 2007 · Pain Medicine
11. Buprenorphine for treating cancer pain
    Cho-Min Naing, Kyan Aung, Peng Nam Yeoh · 2012 · Cochrane Database of Systematic Reviews
12. Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes
    Gary J. Young, Md Mahmudul Hasan, Leonard D. Young, Md. Noor‐E‐Alam · 2023 · Substance Use & Misuse
13. Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
    Zheng Zhang, Qianzhi Yang, Minghao Chen, Wah Yang, Yuping Wang · 2024 · Frontiers in Pharmacology
14. Treatment of Pain and Opioid Abuse
    Shanthi Mogali, Sandra D. Comer · 2013 · ACS symposium series
15. Implementing parity for mental health and substance use treatment in Medicaid
    Marguerite E Burns, Laura Dague, Brendan Saloner, Kristen Voskuil, Nam Hyo Kim, Natalia Serna Borrero, Kevin Look · 2020 · Health Services Research
16. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic
    Jocelyn R. James, Marissa Marolf, Jared Wilson Klein, Kendra L. Blalock, Joseph O. Merrill, Judith I. Tsui · 2021 · Substance Use & Misuse
17. GSK3β Activity in Reward Circuit Functioning and Addiction
    Jakub Turlik, Ewa Wąsikiewicz, Aleksandra Domaradzka, Gabriela Chrostek, Weronika Gniadzik, Mikołaj Domagalski, Przemysław Duda · 2021 · NeuroSci
18. 2012 Update in addiction medicine for the generalist
    For the US Society of General Internal Medicine’s Substance Abuse Interest Group, Darius A. Rastegar, Hillary V. Kunins, Jeanette M. Tetrault, Alexander Yale Walley, Adam J. Gordon · 2013 · Addiction Science & Clinical Practice
19. Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling
    Mo’tasem M. Alsmadi · 2024 · Therapeutic Drug Monitoring
20. Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge
    Steven L. Proctor, Autumn Birch, Philip L. Herschman · 2018 · Journal of Addiction Medicine
21. A retrospective cohort study of medication dispensing at pharmacies: Administration matters!
    Morten Hesse, Birgitte Thylstrup, Abdu Kedir Seid, Christian Tjagvad, Thomas Clausen · 2021 · Drug and Alcohol Dependence
22. Outcomes from the International Survey Informing Greater Insights in Opioid Dependence Treatment (INSIGHT) project
    Adrian Octavian Abagiu, Zrinka Ćavar, Pinhas Nadim Dannon, Philip George, Bogusław Habrat, Zubeida Mahomedy, Petr Popov, Riza Sarasvita, Diah Setia Utami, Andrej Kastelič · 2014 · Drugs Education Prevention and Policy
23. Pharmacist Influence in Buprenorphine Treatment Outcomes for Opioid Dependence
    John R. Tomko, Vincent J. Giannetti · 2006 · Annals of Pharmacotherapy
24. Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence
    Joe Dooley, Lianne Gerber-Finn, Irwin Antone, John Guilfoyle, Brittany Blakelock, Jazmyn Balfour-Boehm, Wilma M. Hopman, Naana Afua Jumah, Len Kelly · 2016 · Canadian Family Physician
25. Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
    Todd D. Molfenter, Carol Sherbeck, Sandy Starr, Jee-Seon Kim, Mark E. Zehner, Andrew Quanbeck, Nora A. Jacobson, Dennis W. McCarty · 2017 · Journal of Addiction Medicine
26. Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
    Niraj R. Chavan, Kristin B. Ashford, Amanda Thaxton Wiggins, Michelle R. Lofwall, Agatha S. Critchfield · 2017 · American Journal of Perinatology Reports
27. HIV Disease Among Substance Users: Treatment Issues
    Robert Douglas Bruce, Frederick Lewis Altice, Gerald H Friedland · 2008 · Elsevier eBooks
28. Pharmacological Treatment of Substance Abuse Disorders
    Wilfrid N. Raby, John J. Mariani, FRANCES RUDNICK LEVIN, Edward V. Nunes · 2015 · Wiley eBooks
29. Buprenorphine Implants and Opioid Dependence
    Debasish Basu · 2011 · JAMA
30. Office-Based Treatment of Opiate Addiction
    Howard A. Heit, Douglas L Gourlay · 2003 · New England Journal of Medicine
31. Effects of live-online, group mindfulness training on opioid use and anxiety during buprenorphine treatment: A comparative effectiveness RCT
    Rosansky, Joseph A., Howard, Leah, Goodman, Hannah, Okst, Kayley, Fatkin, Thomas, Fredericksen, A. Kiera, Sokol, Randi, Gardiner, Paula, Parry, Gareth, Cook, Benjamin L. et al. · 2024 · Contemporary Clinical Trials
32. Antenatal Exposure to Medication for Opioid Use Disorder and Infant Outcomes in the Eat, Sleep, Console for Neonatal Opioid Withdrawal Randomized Controlled Trial
    Sandra Sundquist Beauman, Zhuopei Hu, Ward R. Rice, Lori A. Devlin, Stephanie L. Merhar, Camille M. Fung, Jaime Brown, Ahmed Osman, Adrienne Pahl, Kara Wong Ramsey et al. · 2025 · The Journal of Pediatrics
33. “SafetyNet”: Evaluation of a Recovery Coach and Paramedic Intervention Following Naloxone Resuscitation From an Opioid Overdose
    Daniel Joseph, Carolyn Brokowski, Gail D’Onofrio, Sandy Bogucki, J. McGovern, Rebecca Allen, James Dziura, D. C. Cone, Michael Pantalon · 2024 · Substance use & addiction journal
34. Buprenorphine for pain management physicians: A dilemma or a therapeutic alternative?
    David P. Myers, Michael Augustyniak, Joseph Molea · 2005 · Techniques in Regional Anesthesia and Pain Management
35. Unhealthy substance use in older adults
    Alison A. Moore, Lucia Loredana Dattoma, Aaron Kaufman, Alexis Kuerbis · 2016 · Cambridge University Press eBooks
36. Buprenorphine: Side Effects and Tolerability
    Tabitha A. Washington, Gilbert J. Fanciullo · 2013 · Springer eBooks
37. “I’m Not a Good Drug Dealer”: Styles of Buprenorphine Diversion in a Multisite Qualitative Study
    Katherine J. McLean, Philip R. Kavanaugh · 2022 · Substance Use & Misuse
38. Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples: Can They be Detected When Buprenorphine/Naloxone Film is Dipped into Urine or Water?
    Hiroko Furo, Marisa Whitted, Tony Lin, Yi Yuan Zhou, Sarah Abdelsayed, Bradley B. Brimhall, Peter L. Elkin · 2024 · Substance Use Research and Treatment
39. At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead
    Jaskaran Singh Dhillon, Leah Feulner, Ariya Beitollahi, Kelly Kossen, David W. Galarneau · 2024 · Ochsner Journal
40. Buprenorphine for opioid addiction
    Walter W Ling, Larissa J. Mooney, Matthew Torrington · 2013 · Neuropsychiatry
41. Pharmacotherapies for treating opioid use disorder
    Thomas A. Nguyen, Jennie H. Hahn, Stephen M. Strakowski · 2013 · CNS Spectrums
42. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double‐blind, within‐subject, crossover study among opioid‐dependent subjects
    Naveen Kumar Dhagudu, Atul Ambekar, Alok Chandra Agrawal, Ravindra Rao, Ashwani Kumar Mishra, Raka Jain, Shalini Singh · 2020 · Drug and Alcohol Review
43. Inducción a buprenorfina sublingual desde metadona: estudio clínico descriptivo en una muestra de pacientes tratados en una comunidad terapéutica
    Francisco González‐Sáiz, Josefa Gutiérrez Ortega, Izaskun Bilbao Acedos, Rosario Ballesta Gómez, Oscar Martin Lozano · 2008 · Trastornos Adictivos
44. Aspectos farmacológicos de los programas de tratamiento con buprenorfina-naloxona
    Francisco González‐Sáiz, E. Alvarez · 2008 · Trastornos Adictivos
45. Personality Disorders
    Lois Wonsun Choi-Kain, Ana M. Rodriguez-Villa, Gabrielle S. Ilagan, Evan Alexander Iliakis · 2021 · Cambridge University Press eBooks
46. A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practices: The HOMER study protocol
    Douglas H. Fernald, Donald E. Nease, John M. Westfall, Bethany M. Kwan, L. Miriam Dickinson, Ben Sofie, Cory B. Lutgen, Jennifer K. Carroll, David Wolff, Lori Heeren et al. · 2023 · PLoS ONE
47. Assessment of harm reduction receipt and infectious diseases outcomes in United States Veterans with opioid use disorder and history of injection drug use
    Khushbu P. Shah, Pronoma Srivastava, Viraj I. Modi, Audun Lier · 2024 · Harm Reduction Journal
48. Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder
    Matthew Heshmatipour, Tyler M. Duvernay, Desislava Z. Hite, Eboo Versi, Michael P. Hite, David Reeser, Victor Prikhodko, Ariana Marie Nelson, Bina Julian, Milton L. Greenberg · 2025 · Addiction Science & Clinical Practice
49. A survey of pharmacy experiential learning in substance dependence
    Dongmi Kim, Bethany A. DiPaula · 2013 · Currents in Pharmacy Teaching and Learning
50. Buprenorphine Implants and Opioid Dependence—Reply
    Walter W Ling · 2011 · JAMA
51. Long-term Suboxone Treatment and its Benefit on Long-Term Remission for Opiate Dependence
    Anish S Shah James Young · 2014 · African Journal of Psychiatry
52. Substance Use Disorders
    David John Kavanagh, Jason P. Connor, Ross McD. Young · 2009 · Springer eBooks
53. Factors Affecting Norbuprenorphine Level in Monitoring Clinical Outcome for Buprenorphine-maintained Patients
    Ayman Fareed, Kelly Scheinberg, Sreedevi Vayalapalli, Steven C. Stout, Robin Blackinton Gale, Aalok Chandora, Karen P. G. Drexler · 2012 · Addictive Disorders & Their Treatment
54. Craving and Depression in Opiate Dependent Mentally Ill African Americans Receiving Buprenorphine/Naloxone and Group CBT (Cognitive Behavioral Therapy)
    Tanya N. Alim, Suneeta Kumari, Leslie B. Adams, Didier Anton Saint Cyr, Steven J. Tulin, Elizabeth Carpenter Song, Maria Mananita S Hipolito, Loretta Peterson, William B. Lawson · 2017 · Clinical Psychiatry
55. Isolation, Identification and Structural Verification of a Methylene-Bridged Naloxone “Dimer” Formed by Formaldehyde
    Philipp Schmidt, Christine Kolb, Andreas Reiser, Markus Philipp, Hans-Christian Müller, Konstantin Karaghiosoff · 2021 · Journal of Pharmaceutical Sciences
56. Safe use of opioids
    Se‐Il Go, Young‐Woong Won, Jung Hun Kang · 2022 · Journal of Korean Medical Association
57. An Overview of Pain Management
    June L. Dahl · 2005 · Journal of Medical Regulation
58. Clinical Toxicology
    Loralie J. Langman, Laura K. Bechtel, Christopher P. Holstege · 2012 · Elsevier eBooks
59. Toward evaluation of disseminated effects of medications for opioid use disorder within provider‐based clusters using routinely‐collected health data
    Ashley L Buchanan, Tianyu Sun, Jing Hui Wu, Hilary A. Aroke, Jeffrey P. Bratberg, Josiah D. Rich, Stephen J Kogut, Joseph W. Hogan · 2022 · Statistics in Medicine
60. Buprenorphine Program Evaluation in a Private Psychiatric Office-Based Practice
    Joshua David Palmer, Ann M. Mitchell, Elizabeth A. Schlenk, Prabir K. Mullick, Heeyoung Lee · 2023 · Journal of Addictions Nursing
61. Improving maintenance treatment of opiate addiction: Clinical aspects
    Kaarlo Simojoki · 2013 · Työväentutkimus Vuosikirja
62. Buprenorphine Treatment
    Bradley R. Meier, A. Patkar · 2007 · Journal of Addictive Diseases
63. Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders
    Helen Dermatis, Marc S. Galanter · 2007 · FOCUS The Journal of Lifelong Learning in Psychiatry
64. PREGNANT WOMEN IN OPIOID MAINTENANCE TREATMENT (OMT): MATERNAL AND NEONATAL OUTCOMES
    Ingunn Olea Lund · 2013 · NORA - Norwegian Open Research Archives
65. ABUSED AGENTS
    John C.M. Brust · 2004 · CONTINUUM Lifelong Learning in Neurology
66. Invited Commentary: On the Mathematization of Epidemiology as a Socially Engaged Quantitative Science
    Abigail R. Cartus, Brandon D. L. Marshall · 2023 · American Journal of Epidemiology
67. Pomegranate juice consumption by patients under medication for addiction treatment as regulator of craving and blood redox status: The study protocol of a randomized control trial (the NUTRIDOPE study)
    Christonikos Leventelis, Sotiris K. Tasoulis, Demetrios Kouretas, George S. Metsios, Aristidis S. Veskoukis · 2023 · Research Square
68. Substance Use Disorders
    Hilary Smith Connery, Mark J. Albanese, Jeffrey J. DeVido, Kevin P. Hill, R. Kathryn McHugh, Dana B. Sarvey, Joji Suzuki, Roger D. Weiss · 2021 · Cambridge University Press eBooks
69. The association between medication for opioid use disorder and employment outcomes in the U.S.: The relevance of race and ethnicity
    Bai Linh Hoang, Daniel Sledge · 2022 · Drug and Alcohol Dependence Reports
70. Enhancing distress tolerance to uplift motivation in recovery: Results from an open development trial
    Prachi H. Bhuptani, Amanda Block, Paola Jiménez Muñoz, Mariel S. Bello, Susan E. Ramsey, Megan L. Ranney, Kate Bergmann Carey, Josiah D. Rich, Kirsten J. Langdon · 2023 · Digital Health
71. Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial
    Sterling McPherson, Crystal Lederhos Smith, Luke Hall, André Constantino Miguel, Theresa Bowden, Abigail Keever, Alex Schmidt, Katie Olson, Nicole M. Rodin, Michael G. McDonell et al. · 2024 · Drug and Alcohol Dependence
72. Emergency department buprenorphine program: staff concerns and recommended implementation strategies
    Olufemi Olamide Ajumobi, Sarah A. Friedman, Michelle L. Granner, Julie E. Lucero, John Westhoff, Brandon Koch, Karla D. Wagner · 2024 · Implementation Science Communications
73. Clinical Therapy Dose Optimization of Sublingual Buprenorphine in Poorly Adherent Pregnant Patients: A PBPK Translational Modelling Study
    Tobechı Brendan Nnanna · 2024 · International Journal of Pharmacy and Chemistry
74. Unveiling the Physiological Systemic Consequences of Adolescent Opioid Use: A Systematic Review
    Ajayi Ayodeji Folorunsho, Mega Obukohwo Oyovwi, Oyedayo Phillips Akano, Lateef Olabisi Okeleji, Bernard Opeyemi Adedeji, Ajayi Lydia Oluwatoyin · 2025 · Journal of Child & Adolescent Substance Use
75. Modeling Recurrent Events: A Tutorial Based on Relapse and Remitting Episodes during Medication-Assisted Treatment for Opioid Use Disorder
    Stavroula A. Chrysanthopoulou, Jianing Wang, Shayla Nolen, Anusha Rajapaksha W. M. Madushani, Sean M. Murphy, Benjamin Paul Linas, Laura Forsberg White · 2025 · Medical Decision Making
76. Development of a poly(2,6-diaminopyridine)-coated magnetic porous carbon nanosorbent for simultaneous dispersive micro-solid phase extraction of buprenorphine and naloxone from biological fluids
    Farzaneh Mohammadi, Shayessteh Dadfarnia, Ali Mohammad Haji Shabani, Ali Akbar Asgharinezhad · 2026 · Journal of Chromatography A
77. Les opioïdes
    John C.M. Brust · 2007 · Elsevier eBooks
78. Declaración de Socidrogalcohol, Sociedad Española de Toxicomanías (SET) y Sociedad Española de Patología Dual (SEPD) sobre las inequidades de los pacientes especiales respecto a los planes de mantenimiento con agonistas de opiáceos en la cartera de servicios comunes del Sistema Nacional de Salud
    N. Szerman, Julio Bobes, José Pérez de los Cobos · 2009 · Trastornos Adictivos
79. Buprenorphine plus naloxone, a new substitution treatment
    Steve Chaplin, Alan Fraser · 2007 · Prescriber
80. Pharmacopsychosocial Treatment of Opioid Dependence: Harm Reduction, Palliation, or Simply Good Medical Practice?
    Peter R. Martin, Alistair J. Reid Finlayson · 2012 · Dusunen Adam The Journal of Psychiatry and Neurological Sciences
81. Drug Discovery and Development for Reward Disorders: Views from Government
    David J. McCann, Jane B. Acri, Frank J. Vocci · 2008 · Elsevier eBooks
82. Opioids: Heroin and Prescription Drugs
    Jason M. White · 2010 · Springer eBooks
83. HIV disease among substance users
    Robert Douglas Bruce, Frederick Lewis Altice, GERALD H. FRIEDLAND · 2012 · Elsevier eBooks
84. Integrating Treatment for Opioid Use Disorders and HIV Services into Primary Care
    Nabila El‐Bassel, Phillip L. Marotta, L Gilbert, Emma Y. Wu, Sandra Ann Springer, Dawn Goddard‐Eckrich, Timothy Hunt · 2018 · Oxford University Press eBooks
85. Managing Pain during Pregnancy and Lactation
    James P. Rathmell, Christopher M. Viscomi, Marjorie C. Meyer · 2008 · Elsevier eBooks
86. Psychopharmacology and Neurotherapeutics
    Steve J. Seiner, Ross J. Baldessarini, Joan Albert Camprodon, Darin Dean Dougherty, Lior Givon, Jeffrey J. DeVido, Jonathan E. Alpert · 2021 · Cambridge University Press eBooks
87. Global Health and Mental Health Care Delivery in Low-Resource Settings
    Giuseppe J. Raviola · 2021 · Cambridge University Press eBooks
88. Mood Disorders
    Scott R. Beach, Jeff C. Huffman, Ji Hyun Baek, Michael Tilghman Treadway, Andrew Alan Nierenberg, Jonathan E. Alpert · 2021 · Cambridge University Press eBooks
89. Psychometric Characteristics of the Persian Version of the Opiate Dosage Adequacy Scale (ODAS)
    Abdollah Golnezhad, Anahita Torkaman‐Boutorabi, Emran Mohammad Razaghi, Mohammad‐Reza Zarrindast, Sara Yadollahi, Parviz Dousti Kataj, Nasim Vousooghi · 2023 · Basic and Clinical Neuroscience Journal
90. Les effets indésirables des médicaments de substitution dans le traitement de la dépendance aux opioïdes
    Pierre Lauzon · 2012 · Drogues santé et société
91. Substance Use Disorders and Detoxification
    M CLARK · 2005 · Elsevier eBooks
92. Clinical observation Buprenorphine Replacement Therapy for Adolescents with Opioid Dependence: Early Experience from a Children's Hospital-Based Outpatient Treatment Program
    Sharon Levy, Brigid L. Vaughan, John Rogers Knight · 2007
93. Sustained‐release subdermal buprenorphine implants: the future of opioid use disorder management?
    Christopher James Shephard, Aaron D. Drovandi · 2019 · Journal of Pharmacy Practice and Research
94. Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program
    Srinivasa B. Gokarakonda, Jacob M. Boydstun, Musa Yilanli, Xiaotong Han, Nihit Kumar, Alison H. Oliveto, Michael J. Mancino · 2022 · American Journal on Addictions
95. Commentary on Rosenthalet al. (2013): Buprenorphine implant-new hopes, old questions
    Debasish Basu · 2013 · Addiction
96. Buprenorphine for Heroin Addicts
    Elizabeth Cho, Helen Dermatis, Marc S. Galanter · 2006 · Substance Abuse
97. Medication Groups for Office Based Opioid Treatment
    Michael M. Miller · 2007 · Journal of Addiction Medicine
98. Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving
    Linda Gowing, Olga V. Lopatko · 2004 · Evidence-Based Mental Health
99. Buprenorfina en dependencia a opiáceos: reflexiones sobre la seguridad
    J. Javier Meana, J. Pineda · 2005 · Trastornos Adictivos
100. Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
     Frederic R. Curtiss · 2008 · Journal of Managed Care Pharmacy